Award of CLIA Certificate of Registration to HKG Epitherapeutics Ltd. marks a new phase in delivering high-quality laboratory testing services.
HONG KONG, SAR, China – May 2, 2023: HKG Epitherapeutics Ltd., a leading biotech firm dedicated to developing early detection tools based on epigenetic technology, has been awarded the Clinical Laboratory Improvement Amendments (CLIA) Certificate of Registration by the Centers for Medicare & Medicaid Services. This milestone signifies the lab’s enrollment in the CLIA program and allows the facility to begin accepting human specimens for laboratory examinations and procedures.
HKG Epitherapeutics Ltd. is located at Unit 313-515, 3/F Biotech Centre 2, 11 Science Park West Ave, Hong Kong Science Park, Hong Kong. The CLIA Certificate of Registration, with the CLIA ID number 99D2281144, is effective from May 2, 2023, and valid until May 1, 2025. Dr. Carlos Ruiz, M.D., serves as the Laboratory Director.
What the CLIA Registration Means
The CLIA Certificate of Registration is a critical element for any clinical laboratory in the United States, ensuring that the laboratory meets federal standards for quality, reliability, and performance. While this certificate permits HKG Epitherapeutics Ltd. to begin testing, compliance determination will occur once a survey is successfully completed.
Impact and Next Steps
This registration is a significant step forward for HKG Epitherapeutics Ltd., as it is now able to serve a broader range of clients and participate in critical research endeavors. By achieving this milestone, the company demonstrates its commitment to delivering high-quality laboratory testing services that meet rigorous federal standards.
“This CLIA registration is a testament to our dedication to excellence in laboratory services. We are committed to upholding the highest standards and look forward to contributing to the advancement of healthcare through our specialized testing capabilities,” said [Name, Title, HKG Epitherapeutics Ltd.].
About HKG Epitherapeutics Ltd.
HKG Epitherapeutics Ltd. is a pioneering biotech firm focusing on the development of cutting-edge early detection tools utilizing epigenetic technology and advanced next-generation sequencing. Through continual innovation, the company aims to enhance cancer diagnosis, treatment, and patient outcomes.